Akari Therapeutics Plc Stock Investor Sentiment

AKTX Stock  USD 1.00  0.17  14.53%   
Slightly above 54% of Akari Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Akari Therapeutics PLC stock suggests that some investors are interested at this time. Akari Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Akari Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Akari Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Akari Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at www.macroaxis.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 10000000 shares by Prudo-chlebosz Raymond of Akari Therapeutics at 0.0017 subject to ...
Macroaxis News
over six months ago at simplywall.st         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Simply Wall St News at Macroaxis
over six months ago at simplywall.st         
Insiders Who Purchased US1.43m Of Akari Therapeutics Stock May Not Have Expected 21 percent Tumble
Simply Wall St News at Macroaxis
over six months ago at finance.yahoo.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Yahoo News
over six months ago at finance.yahoo.com         
Akari Therapeutics Insider Ups Holding By 69 percent During Year
Yahoo News
over six months ago at globenewswire.com         
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
Macroaxis News: globenewswire.com
over six months ago at www.macroaxis.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Macroaxis News
over six months ago at news.google.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b...
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Akari Therapeutics that are available to investors today. That information is available publicly through Akari media outlets and privately through word of mouth or via Akari internal channels. However, regardless of the origin, that massive amount of Akari data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akari Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akari Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akari Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akari Therapeutics alpha.

Akari Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
StockNews.com Initiates Coverage on Akari Therapeutics
09/17/2024
2
Acquisition by Patel Samir Rashmikant of 175080000 shares of Akari Therapeutics at 0.0015 subject to Rule 16b-3
09/30/2024
3
Disposition of tradable shares by Williams Donald A of Akari Therapeutics subject to Rule 16b-3
10/01/2024
4
Disposition of 1300000 shares by Grissinger Michael of Akari Therapeutics at 0.0218 subject to Rule 16b-3
10/08/2024
5
Acquisition by Patel Samir Rashmikant of 79684000 shares of Akari Therapeutics at 0.0013 subject to Rule 16b-3
10/31/2024
6
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
11/14/2024
7
Insider Trading
11/22/2024
8
Acquisition by Patel Samir Rashmikant of 162604000 shares of Akari Therapeutics at 6.0E-4 subject to Rule 16b-3
11/29/2024
9
Acquisition by Prudo-chlebosz Raymond of 419286000 shares of Akari Therapeutics at 0.0011 subject to Rule 16b-3
12/02/2024
10
Akari Therapeutics Coverage Initiated by Analysts at StockNews.com
12/06/2024

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.